The answer is a complicated one. There are some programs that require a co-funder, which is usually a private sector partner. In effect, this partner has veto power over whether the project gets public money. In other cases, the granting councils themselves, sensitive to the fact that the federal government is putting great emphasis on commercialization, give their programs more of a commercial orientation, believing this to be the best way to encourage the federal government to provide the kind of funding we desperately need in this country.
So some programs require commercial linkages. More informally, a certain pressure guides people to favour projects that may have a commercial bottom line. The difficulty, however, is that our ability to predict commercial success in research is abysmal.
Paul Berg, who got the Nobel prize at Stanford for his research on the splicing of DNA, which arguably helps underwrite the entire biotech industry today, said that if he had had to pass through a commercialization screen to get this money, he wouldn't have gotten a dime. Yet his work now helps to underwrite a multi-billion-dollar industry. If you talk to most scientists, whether it be in physics or biology or chemistry, they'll point out that the most important commercial developments in their field have by and large come from basic research.
So we shouldn't dismiss commercialization, but we should remember that we can't forecast what's going to be of value. We really need to trust good scientists to identify good science. That's what Mike Lazarides and John Polanyi are both saying.